Synovus Financial Corp Gilead Sciences, Inc. Transaction History

Synovus Financial Corp

$8.56 Billion
Q3 2024

A detailed history of Synovus Financial Corp transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Synovus Financial Corp holds 37,265 shares of GILD stock, worth $3.41 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

37,265

Previous 37,265 -0.0%

Holding current value

$3.41 Million

Previous $3.12 Million -0.0%

% of portfolio

0.04%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $1.24 Million - $1.56 Million	18,592 Added 99.57%	37,265 $3.12 Million
Q2 2024 Aug 13, 2024	SELL	$63.15 - $72.88 $2.21 Million - $2.55 Million	-35,002 Reduced 65.21%	18,673 $1.28 Million
Q1 2024 May 14, 2024	SELL	$71.58 - $87.29 $525,468 - $640,795	-7,341 Reduced 12.03%	53,675 $3.93 Million
Q3 2023 Nov 13, 2023	SELL	$73.94 - $80.67 $171,540 - $187,154	-2,320 Reduced 3.66%	61,016 $4.57 Million
Q2 2023 Aug 08, 2023	BUY	$76.01 - $86.7 $3.62 Million - $4.13 Million	47,587 Added 302.16%	63,336 $4.88 Million
Q1 2023 May 11, 2023	BUY	$77.31 - $88.08 $521,224 - $593,835	6,742 Added 74.85%	15,749 $1.31 Million
Q4 2022 Feb 06, 2023	SELL	$62.32 - $89.47 $74,347 - $106,737	-1,193 Reduced 11.7%	9,007 $773,000
Q3 2022 Oct 27, 2022	SELL	$59.54 - $68.01 $28,221 - $32,236	-474 Reduced 4.44%	10,200 $626,000
Q2 2022 Aug 10, 2022	BUY	$57.72 - $65.01 $4,444 - $5,005	77 Added 0.73%	10,674 $658,000
Q1 2022 May 12, 2022	SELL	$57.92 - $72.58 $82,362 - $103,208	-1,422 Reduced 11.83%	10,597 $631,000
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $244,143 - $277,107	-3,763 Reduced 23.84%	12,019 $872,000
Q3 2021 Nov 08, 2021	SELL	$67.69 - $73.03 $153,588 - $165,705	-2,269 Reduced 12.57%	15,782 $1.1 Million
Q2 2021 Aug 11, 2021	BUY	$63.47 - $69.35 $119,006 - $130,031	1,875 Added 11.59%	18,051 $1.24 Million
Q1 2021 May 11, 2021	SELL	$60.0 - $68.46 $198,900 - $226,944	-3,315 Reduced 17.01%	16,176 $1.05 Million
Q4 2020 Feb 11, 2021	SELL	$56.65 - $64.55 $144,457 - $164,602	-2,550 Reduced 11.57%	19,491 $1.14 Million
Q3 2020 Nov 09, 2020	SELL	$62.1 - $78.08 $377,754 - $474,960	-6,083 Reduced 21.63%	22,041 $1.4 Million
Q2 2020 Aug 10, 2020	SELL	$72.34 - $84.0 $930,437 - $1.08 Million	-12,862 Reduced 31.38%	28,124 $2.16 Million
Q1 2020 Apr 24, 2020	BUY	$62.63 - $80.22 $1.07 Million - $1.37 Million	17,136 Added 71.85%	40,986 $3.06 Million
Q4 2019 Feb 06, 2020	SELL	$61.62 - $67.78 $32,843 - $36,126	-533 Reduced 2.19%	23,850 $1.55 Million
Q3 2019 Nov 01, 2019	SELL	$62.51 - $69.0 $55,258 - $60,996	-884 Reduced 3.5%	24,383 $1.55 Million
Q2 2019 Aug 08, 2019	BUY	$61.87 - $69.38 $36,812 - $41,281	595 Added 2.41%	25,267 $1.71 Million
Q1 2019 May 09, 2019	SELL	$62.53 - $70.05 $974,279 - $1.09 Million	-15,581 Reduced 38.71%	24,672 $1.61 Million
Q4 2018 Feb 07, 2019	SELL	$60.54 - $79.0 $3.21 Million - $4.18 Million	-52,974 Reduced 56.82%	40,253 $2.52 Million
Q3 2018 Nov 01, 2018	SELL	$71.28 - $78.92 $216,120 - $239,285	-3,032 Reduced 3.15%	93,227 $7.21 Million
Q2 2018 Aug 01, 2018	SELL	$64.88 - $75.68 $457,728 - $533,922	-7,055 Reduced 6.83%	96,259 $6.83 Million
Q1 2018 May 07, 2018	BUY	$72.84 - $88.8 $345,334 - $421,000	4,741 Added 4.81%	103,314 $7.79 Million
Q4 2017 Feb 09, 2018	SELL	$71.15 - $83.52 $66,382 - $77,924	-933 Reduced 0.94%	98,573 $7.06 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $7.18 Million - $8.5 Million	99,506	99,506 $8.05 Million

Others Institutions Holding GILD

# of Institutions

1,928

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $115B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Synovus Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Synovus Financial Corp with notifications on news.

Account

Synovus Financial Corp Gilead Sciences, Inc. Transaction History